ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020
Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Safety analysis of intraperitoneal hyperthermic chemotherapy in the treatment of gastrointestinal cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- Systematic review and meta-analysis of outcomes associated with incisional and organ/space surgical site infections in abdominal surgery patients.Antimicrobial resistance and infection control · 2025Pooled it
- Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers.PeerJ · 2023Pooled it
- Predicting Postoperative Infection After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Splenectomy.Annals of surgical oncology · 2025Article
- Review
- Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Patients at High Risk of Developing Gallbladder Cancer Peritoneal Metastases: Case Report and Rationale for a Prospective Clinical Trial.Journal of clinical medicine · 2024Review
- Side-Effects on the Renal function of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.International journal of medical sciences · 2024Article
- Challenges following CRS and HIPEC surgery in cancer patients with peritoneal metastasis: a comprehensive review of clinical outcomes.Frontiers in surgery · 2024Review
- Postoperative Bloodstream Infections in Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Risk Factors and Pathogen Resistance.Infection and drug resistance · 2024Article
- Article
- Letter to Smibert OC et al. 'Epidemiology and risk for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy'.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Letter in reply to Carboni F et al.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy Combined with Radical Surgery and Capecitabine on Stage III Gallbladder Cancer.Canadian journal of gastroenterology & hepatology · 2021Article
- Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCRS-HIPEC is associated with improved cancer survival but an increased risk of infection.
methodsConsecutive patients undergoing CRS-HIPEC between January 2016 and May 2018 were retrospectively reviewed. Malignancy type, comorbidities, perioperative risk factors and infectious complications were captured, using standardised definitions. Association between risk factors and infection outcomes was evaluated by logistic regression modelling.
resultsOne-hundred patients underwent CRS-HIPEC, predominantly for colorectal cancer and pseudomyxoma peritonei. Overall, 43 (43.0%) experienced an infectious complication, including infections at surgical site (27), respiratory tract (9), urinary tract (11), Clostridium difficile (2) and post-operative sepsis (15). In most, infection onset was within 7 days post-operatively. Median length of hospitalisation was 19 days for patients with infection, compared to 8 days for those without (p = 0.000). There were no deaths at 60 days. Of variables potentially associated with surgical site infection, small bowel resection (OR 4.01, 95% confidence interval [CI] 1.53-10.83; p = 0.005) and number of resected viscera (OR 1.41, 95% CI 1.00-1.98; p = 0.048) were significantly associated with infection.
conclusionsWe demonstrate a significant burden of early infective complications in patients undergoing CRS-HIPEC. Higher-risk subgroups, including those with small bowel resection and increased number of resected viscera, may benefit from enhanced monitoring.
Indexed as
Identifiers
31712951What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.